- Half Year 2023 Poxel SA Earnings Call TranscriptSep 26, 2023€0.401 (-20.59%)Earnings
- Q4 2022 Poxel SA Earnings Call TranscriptMar 23, 2023€0.735 (-3.29%)Earnings
- Half Year 2022 Poxel SA Earnings Call TranscriptSep 21, 2022€2.08 (+1.96%)Earnings
- Full Year 2021 Poxel SA Earnings Call TranscriptMar 22, 2022€2.75 (+2.00%)Earnings
- Half Year 2021 Poxel SA Earnings Call(English) TranscriptSep 23, 2021€6.33 (+1.20%)Earnings
- Poxel SA New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Corporate Call TranscriptJul 12, 2021
- Full Year 2020 Poxel SA Earnings Call TranscriptMar 25, 2021€6.68 (-0.30%)Earnings
- Poxel S.A. - Special Call TranscriptDec 14, 2020
- Poxel S.A. - Special Call TranscriptOct 01, 2020
- Half Year 2020 Poxel SA Earnings Call TranscriptSep 15, 2020€6.47 (+4.35%)Earnings
- Full Year 2019 Poxel SA Earnings Call TranscriptMar 26, 2020€6.88 (+18.21%)Earnings
- Poxel SA - Special Call TranscriptDec 20, 2019
- Poxel SA - Special Call TranscriptNov 26, 2019
- Half Year 2019 Poxel SA Earnings Call TranscriptAug 26, 2019€6.3 (-1.25%)Earnings
- Poxel SA - Special Call TranscriptJun 25, 2019
- Poxel SA - Special Call TranscriptApr 09, 2019
- Full Year 2018 Poxel SA Earnings Call TranscriptMar 21, 2019€7.87 (+0.38%)Earnings
Poxel SA - Special Call Transcript
Ladies and gentlemen, welcome to the Poxel Conference Call. I now hand call over to Jonae Barnes. Madam, please go ahead.
Thank you for joining us today. With me on the call are Thomas Kuhn , CEO; Christophe Arbet-Engels, Chief Medical Officer and EVP Late Development and Medical Affairs; Pascale Fouqueray, EVP of Early Development and Translational Medicine; and Renevot, our Chief Financial Officer; and Noah Beerman, President of U.S. Operations and Executive Vice President of Business Development. Before we begin, I would like to read our forward-looking statement. Some of the statements contained in this presentation constitute forward-looking statements, which are statements that are not historical facts. These statements are based on the company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should, therefore, not place undue reliance on these statements.
The company makes no representation, warranty or prediction that the results anticipated by
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)